Strongbridge Biopharma (SBBP) PT Set at $14.00 by Cantor Fitzgerald

Strongbridge Biopharma (NASDAQ:SBBP) has been given a $14.00 price objective by analysts at Cantor Fitzgerald in a report issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 67.66% from the company’s current price.

The analysts wrote, “Acquisition of U.S. and Canadian rights to MACRILEN, marks early start to commercialize in rare endocrine disorders.””

Several other research firms also recently commented on SBBP. BidaskClub raised Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Zacks Investment Research downgraded Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. ValuEngine downgraded Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.81.

Strongbridge Biopharma (SBBP) traded up $0.35 during trading on Wednesday, reaching $8.35. The company’s stock had a trading volume of 238,100 shares, compared to its average volume of 220,300. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89. Strongbridge Biopharma has a twelve month low of $2.10 and a twelve month high of $8.85. The company has a market capitalization of $286.50, a P/E ratio of -2.46 and a beta of 2.60.

Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.07. equities analysts expect that Strongbridge Biopharma will post -2.86 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $331,000. Citigroup Inc. bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $338,000. Lyon Street Capital LLC bought a new position in shares of Strongbridge Biopharma during the third quarter valued at $2,862,000. Northern Trust Corp bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $1,462,000. Finally, TIAA CREF Investment Management LLC bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $449,000. 63.96% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3142661/strongbridge-biopharma-sbbp-pt-set-at-14-00-by-cantor-fitzgerald.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.